These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. The pharmacokinetics of oral fleroxacin and ciprofloxacin in plasma and sputum during acute and chronic dosing. Begg EJ; Robson RA; Saunders DA; Graham GG; Buttimore RC; Neill AM; Town GI Br J Clin Pharmacol; 2000 Jan; 49(1):32-8. PubMed ID: 10606835 [TBL] [Abstract][Full Text] [Related]
30. Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers. Chukwuani CM; Coker HA; Oduola AM; Sowunmi A; Ifudu ND Biol Pharm Bull; 2000 Aug; 23(8):968-72. PubMed ID: 10963305 [TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of Ro 23-9424, a dual-action cephalosporin, in animals. Christenson JG; Chan KK; Cleeland R; Dix-Holzknecht B; Farrish HH; Patel IH; Specian A Antimicrob Agents Chemother; 1990 Oct; 34(10):1895-900. PubMed ID: 2127171 [TBL] [Abstract][Full Text] [Related]
32. Comparative oral pharmacokinetics of fleroxacin and pefloxacin. De Lepeleire I; Van Hecken A; Verbesselt R; Tjandra-Maga TB; De Schepper PJ J Antimicrob Chemother; 1988 Aug; 22(2):197-202. PubMed ID: 3141343 [TBL] [Abstract][Full Text] [Related]
33. Single-dose pharmacokinetic study of ciprofloxacin and fleroxacin in healthy adult Nigerian volunteers. Chukwuani CM; Coker HA; Oduola AM; Ifudu ND; Sowunmi A Chemotherapy; 1998; 44(6):369-76. PubMed ID: 9755295 [TBL] [Abstract][Full Text] [Related]
34. Interaction between theophylline and enoxacin. Takagi K; Hasegawa T; Yamaki K; Suzuki R; Watanabe T; Satake T Int J Clin Pharmacol Ther Toxicol; 1988 Jun; 26(6):288-92. PubMed ID: 3165968 [TBL] [Abstract][Full Text] [Related]
35. Inhibition of theophylline clearance by coadministered ofloxacin without alteration of theophylline effects. Gregoire SL; Grasela TH; Freer JP; Tack KJ; Schentag JJ Antimicrob Agents Chemother; 1987 Mar; 31(3):375-8. PubMed ID: 3472488 [TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics and body fluid penetration of fleroxacin in healthy volunteers. Sorgel F; Metz R; Naber K; Seelmann R; Muth P J Antimicrob Chemother; 1988 Oct; 22 Suppl D():155-67. PubMed ID: 3144534 [TBL] [Abstract][Full Text] [Related]
37. Fleroxacin in single dose oral therapy of uncomplicated lower urinary tract infection. Kosmidis J; Gargalianos P; Adamis G; Petropoulou D; Makris D J Antimicrob Chemother; 1988 Oct; 22 Suppl D():219-21. PubMed ID: 3144541 [TBL] [Abstract][Full Text] [Related]
38. Determination of the new fluoroquinolone fleroxacin and its N-demethyl and N-oxide metabolites in plasma and urine by high-performance liquid chromatography with fluorescence detection. Heizmann P; Dell D; Eggers H; Gora R J Chromatogr; 1990 Apr; 527(1):91-101. PubMed ID: 2114419 [TBL] [Abstract][Full Text] [Related]
39. First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers. Jiao Y; Kim TH; Tao X; Kinzig M; Landersdorfer CB; Drescher SK; Sutaria DS; Moya B; Holzgrabe U; Sörgel F; Bulitta JB Eur J Pharm Sci; 2018 Oct; 123():416-428. PubMed ID: 30076955 [TBL] [Abstract][Full Text] [Related]